Statistically significant association of glioblastoma immunotherapy phase II clinical study (ICT-107) treatment and survival to immune response using a novel comprehensive ELISPOT analysis.

Event Name/Location

The 20th Annual Scientific Meeting and Education Day for the Society for Neuro-Oncology; 2015 November 19-22; San Antonio, TX

Presentation Date

11-2015

Document Type

Poster

Presenters / Authors

Radleigh Santos, Torrey Pines Institute for Molecular StudiesFollow
Anthony Gringeri, ImmunoCellular Therapeutics Ltd
John Yu
Sylvia Janetzki, ZellNet Consulting
Valeria A. Judkowski, Torrey Pines Institute for Molecular Studies (TPIMS)
Clemencia Pinilla, Torrey Pines Institute for Molecular Studies

NSUWorks Citation

Santos, Radleigh; Gringeri, Anthony; Yu, John; Janetzki, Sylvia; Judkowski, Valeria A.; and Pinilla, Clemencia, "Statistically significant association of glioblastoma immunotherapy phase II clinical study (ICT-107) treatment and survival to immune response using a novel comprehensive ELISPOT analysis." (2015). Mathematics Faculty Proceedings, Presentations, Speeches, Lectures. 374.
https://nsuworks.nova.edu/cnso_math_facpres/374